MicroRNA-941-2 (MIR941-2)

MicroRNA-941-2 is a human-specific microRNA that regulates gene expression post-transcriptionally, mainly by binding to complementary sequences in the 3′ UTRs of mRNAs and suppressing their translation or promoting degradation. It is highly expressed in pluripotent cells and is downregulated upon differentiation. Its main biological actions include regulating cell proliferation, apoptosis, cell cycle progression, and inflammation. MIR941-2 is frequently upregulated in malignant cells, including breast, lung, hepatocellular, and skin cancers, where it is associated with oncogenic phenotypes. It also functions as a promising biomarker for acute coronary syndrome, demonstrating a graded elevation with increasing severity of disease. Mechanistically, miR-941-2 regulates diverse cellular pathways including MAPK signaling, Wnt signaling, TGF-β, insulin signaling, autophagy, and immune signaling. No small-molecule drugs are currently known to specifically target miR-941-2; instead, experimental interventions employ antisense oligonucleotides, inhibitors, and epigenetic modulators to alter its activity. No major nomenclature errors are noted in "MIR941-2"; it is a well-characterized miRNA, not a receptor, transporter, enzyme, or classical target, but fits the category of a regulatory RNA "target" in modern therapeutic research.

Other names

MIR941-2hsa-mir-941-2MIRN941-2microRNA 941-2miR-941-2miR-941

Targeted inhibition (by antisense oligonucleotides or miRNA inhibitors); Modulation by small molecule epigenetic drugs (indirect regulation, e.g., methyltransferase inhibitors); Potential future targeting by RNA therapeutics (antisense, mimics, RNAi).